Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: Results of the AIDS Clinical Trials Group A5211

Clinical Infectious Diseases

Volumn 48, Issue 5, 2009, Pages 642-649

  Tsibris, Athe M N ^a   Paredes, Roger ^a,i   Chadburn, Amy ^b   Su, Zhaohui ^a   Henrich, Timothy J ^a   Krambrink, Amy ^a   Hughes, Michael D ^a   Aberg, Judith A ^c   Currier, Judith S ^d   Tashima, Karen ^e   Godfrey, Catherine ^f   Greaves, Wayne ^h   Flexner, Charles ^g   Skolnik, Paul R ^a   Wilkin, Timothy J ^b   Gulick, Roy M ^b   Kuritzkes, Daniel R ^a,j  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BELLEVUE HOSPITAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MIRIAM HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ IrsiCaixa Foundation   (Spain)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHEMOKINE RECEPTOR CCR5; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN; ETOPOSIDE; PREDNISONE; RITUXIMAB; VICRIVIROC; VINBLASTINE; VINCRISTINE; VIRUS DNA; 1 ((4,6 DIMETHYL 5 PYRIMIDINYL)CARBONYL) 4 (4 (2 METHOXY 4 (TRIFLUOROMETHYL)PHENYL)ETHYL 3 METHYL 1 PIPERAZINYL) 4 METHYLPIPERIDINE; 1-((4,6-DIMETHYL-5-PYRIMIDINYL)CARBONYL)-4-(4-(2-METHOXY-4-(TRIFLUOROMETHYL)PHENYL)ETHYL-3-METHYL-1-PIPERAZINYL)-4-METHYLPIPERIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; CAUSAL ATTRIBUTION; CLINICAL STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; EPSTEIN BARR VIRUS; HISTOCHEMISTRY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; BLOOD; CLINICAL TRIAL; ISOLATION AND PURIFICATION; LYMPHOMA; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; VIROLOGY; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; VIRAL LOAD;

EID: 60549115340     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597007     Document Type: Article

References (42)

1. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97:1165-71.
2. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol 2007; 60:1365-72.
3. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-41.
4. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-55.
5. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197:721-7.
6. Murga JD, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006; 50:3289-96.
7. Carr DJ, Ash J, Lane TE, Kuziel WA. Abnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1. J Gen Virol 2006; 87(Pt 3):489-99.
8. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005; 202:1087-98.
9. Glass WG, McDermott DH, Lim JK, et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006; 203:35-40.
10. Huffnagle GB, McNeil LK, McDonald RA, et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999; 163:4642-6.
11. Zhou Y, Kurihara T, Ryseck RP, et al. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J Immunol 1998; 160:4018-25.
12. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-9.
13. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-5.
14. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-12.
15. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:260-3.
16. Dehee A, Asselot C, Piolot T, et al. Quantification of Epstein-Barr virus load in peripheral blood of human immunodeficiency virus-infected patients using real-time PCR. J Med Virol 2001; 65:543-52.
17. Biggar RJ, Curtis RE, Cote TR, Rabkin CS, Melbye M. Risk of other cancers following Kaposi's sarcoma: relation to acquired immunodeficiency syndrome. Am J Epidemiol 1994; 139:362-8.
18. Rabkin CS. Epidemiology of AIDS-related malignancies. Curr Opin Oncol 1994; 6:492-6.
19. Spina M, Berretta M, Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 2003; 17:843-58.
20. Ambinder RF. Epstein-Barr virus and Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007; 2007:204-9.
21. Bubman D, Cesarman E. Pathogenesis of Kaposi's sarcoma. Hematol Oncol Clin North Am 2003; 17:717-45.
22. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-91.
23. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38:712-5.
24. Bossolasco S, Cinque P, Ponzoni M, et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 2002; 8:432-8.
25. Stevens SJ, Blank BS, Smits PH, Meenhorst PL, Middeldorp JM. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS 2002; 16:993-1001.
26. Ling PD, Vilchez RA, Keitel WA, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 37:1244-9.
27. Van Baarle D, Wolthers KC, Hovenkamp E, et al. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002; 186:405-9.
28. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999; 84:442-8.
29. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br J Haematol 2000; 111:239-46.
30. O'Sullivan CE, Peng R, Cole KS, et al. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol 2002; 67:320-6.
31. Righetti E, Ballon G, Ometto L, et al. Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002; 16:63-73.
32. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12:312-25.
33. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992; 3(Suppl 4):117-28.
34. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318:76-81.
35. Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993; 11:225-32.
36. Lim ST, Levine AM. Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. CA Cancer J Clin 2005; 55:229-41, 260-1, 264.
37. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-12.
38. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-44.
39. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-d32mutation. Cancer Res 1999; 59:3561-4.
40. Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39:1211-6.
41. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198:1113-22.
42. Zingman B SJ, DeJesus E, Slim J, et al. Vicriviroc, a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results [abstract 39LB]. In: Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections (Boston). 2008.